Association of 5′-CpG island hypermethylation of the FHIT gene with lung cancer in Southern-central Chinese population

Cancer Biology and Therapy

Volumn 10, Issue 10, 2010, Pages 997-1000

  Li, Wen ^a   Deng, Jing ^b   Jiang, Pei ^a,b   Tang, Jianxin ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

FHIT gene; Hypermethylation; Lung cancer

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; ACID ANHYDRIDE HYDROLASE; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; ADENOCARCINOMA; ASIAN; CASE CONTROL STUDY; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA;

ACID ANHYDRIDE HYDROLASES; ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 78549260768     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.10.13231     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59:225-49.
2. Jin YT, Xu YC, Yang RD, Huang CF, Xu CW, He XZ. Familial aggregation of lung cancer in a high incidence area in China. Br J Cancer 2005; 92:1321-5.
3. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002; 8:514-9.
4. Chen Q, Lipkina G, Song Q, Kramer RH. Promoter methylation regulates cadherin switching in squamous cell carcinoma. Biochem Biophys Res Commun 2004; 315:850-6. (Pubitemid 38249381)
5. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24:132-8. (Pubitemid 30094712)
6. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2005; 2:4-11.
7. Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann Surg 2001; 234:10-20.
8. Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 2008; 23:81.
9. Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Korbi S. Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol 2008; 19:1774-86.
10. Nephew KP. What will it take to obtain DNA methylation markers for early cervical cancer detection. Gynecol Oncol 2009; 112:291-2.
11. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-9. (Pubitemid 32695003)
12. Agrawal S, Moorchung N, Priya P, Kapoor VK. Human cancers and the FHIT gene. Asia-Pacific Journal of Clinical Oncology 2006; 2:273-9.
13. Shi Y, Zou M, Farid RN, Paterson CM. Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene,with the ubiquitin-conjugating enzyme hUBC9. Biochem J 2000; 352:443-8.
14. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002; 21:6915-35.
15. Huang LW, Chao SL, Chen TJ. Reduced Fhit expression in cervical carcinoma: correlation with tumor progression and poor prognosis. Gynecol Oncol 2003; 90:331-7.
16. Neyaz MK, Kumar RS, Hussain S, Naqvi SH, Kohaar I, Thakur N, et al. Effect of aberrant promoter methylation of FHIT and RASSF1A genes on sudceptibility to cervical cancer in a North Indian population. Biomarkers 2008; 13:597-606.
17. Sozzi G, Veronese M, Negrini M, Baffa R, Cotticelli MG, Croce CM. The FHIT gene at 3p14.2 is abnormal in lung Cancer. Cell 1996; 85:17-26. (Pubitemid 26116803)
18. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 2002; 3:748-54.
19. Cecener G, Tunca B, Egeli U, Karadag M, Vatan O, Uzaslan E, Tolunay S. Mutation analysis of the FHIT gene in bronchoscopic specimens from patients with suspected lung cancer. Tumori 2008; 94:845-8.
20. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59:67-70. (Pubitemid 29062958)
21. Stein CK, Glover TW, Palmer JL, Glisson BS. Direct correlation between FRA3B expression and cigarette smoking. GenesChromosomes Cancer 2002; 34:333-40.
22. Mascaux C, Martin B, Verdebout JM, Meert AP, Ninane V, Sculier JP. Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53. Eur Respir J 2003; 21:753-8.
23. D'Agostini F, Izzotti A, Balansky R, Zanesi N, Croce CM, De Flora S. Early loss of fhit in the respiratory tract of rodents exposed to environmental cigarette smoke. Cancer Res 2006; 66:3936-41.
24. Kim JS, Kim H, Shim YM, Han J, Park J, Kim DH. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis 2004; 25:2165-71.
25. Lin J, Yao DM, Qian J, Wang YL, Han LX, Jiang YW, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leukemia Research 2008; 32:1541-5. (Pubitemid 351796745)
26. Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X, et al. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999; 59:4798-803.
27. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 2002; 3:748-54.
28. Ki KD, Lee SK, Tong SY, Lee JM, Song DH, Chi SG, et al. Role of 5'-CpG island hypermethylation of the FHIT gene in cervical carcinoma. J Gynecol Oncol 2008; 19:117-22.
29. Geradts J, Fong KM, Zimmerman PV, Minna JD. Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer 2000; 82:1191-7. (Pubitemid 30128878)
30. Zöchbauer-Müller S, Wistuba II, Minna JD, Gazdar AF. Fragile histidine triad (FHIT) gene abnormalities in lung cancer. Clin Lung Cancer 2000; 2:141-5. (Pubitemid 32258076)
31. Verri C, Roz L, Conte D, Liloglou T, Livio A, Vesin A, et al. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. Am J Respir Crit Care Med 2009; 179:396-401.
32. Kim DS, Cha SI, Lee JH, Lee YM, Choi JE, Kim MJ, et al. Aberrant DNA methylation profiles of non-small cell lung cancers in a Korean population. Lung Cancer 2007; 58:1-6.